News | June 06, 2022
Proxygen and Merck collaborates to develop molecular glue degraders
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
India is at a key inflexion point of not just ‘Heal in India’ through its vibrant medical value tourism, but also ‘Heal by India’, where our medical professionals can be used to serve not just our country but at the global level.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
